Today, the FDA approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.
Read more: FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer